北京阳光诺和药物研究股份有限公司 2025 年第四次临时股东会补充会议资料 证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 2025 年第四次临时股东会补充会议资料 二〇二五年十一月 1 / 38 北京阳光诺和药物研究股份有限公司 2025 年第四次临时股东会补充会议资料 北京阳光诺和药物研究股份有限公司 2025 年第四次临时股东会补充会议资料目录 | 2025 年第四次临时股东会会议须知 3 | | --- | | 2025 年第四次临时股东会会议议程 6 | | 议案二：关于公司发行股份及可转换公司债券购买资产并募集配套资金暨关联交易方 | | 案（调整后）的议案 10 | | 议案三：关于《阳光诺和发行股份及可转换公司债券购买资产并募集资金暨关联交易 | | 报告书（草案）（修订稿）》及其摘要的议案 35 | | 议案二十六：关于签署附条件生效的《发行股份及可转换公司债券购买资产之业绩补 | | 偿协议之补充协议》的议案 36 | | 议案二十七：关于提请股东会批准利虔及其一致行动人免于以要约方式增持公司股份 | | 的议案 37 | 重要提示：除上述议案外，其余会议资料 ...

Core Insights - The medical services sector experienced a rise of 1.67% on October 31, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 34.46, up 11.20% with a trading volume of 158,200 shares and a transaction value of 530 million [1] - Other notable performers included: - Nanmo Biological (688265) at 50.60, up 9.98% [1] - Nuo Si Ge (301333) at 68.59, up 7.00% [1] - Yangguang Nuohe (688621) at 58.75, up 5.10% [1] - *ST Biological (000504) at 9.57, up 5.05% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 461 million from institutional investors, while retail investors experienced a net inflow of 918,230 [2] - Notable capital flows included: - Innovation Medical (002173) with a net inflow of 14.416 million from institutional investors [3] - Tai Ge Medical (300347) with a net inflow of 70.6534 million from institutional investors [3] - Zhaoyan New Drug (603127) with a net inflow of 53.6731 million from institutional investors [3]

Core Insights - The 2025 High-Quality Development Forum and the 27th Golden Bull Award Ceremony were held in Nantong, Jiangsu, with the theme "Moving Towards New Heights, Achieving Practical Results, and Enlightening the Future" [1] - Sunshine Nuohuo won the "New Quality Enterprise Golden Bull Award" due to its strong development momentum and stable operating performance [1][5] Group 1: Award Overview - The Golden Bull Award, established in 1999 by China Securities Journal, aims to create a credible and authoritative platform for showcasing listed companies in the capital market [4] - The award recognizes companies with standardized governance, performance growth, and positive shareholder and societal returns [4] Group 2: Award Categories and Winners - This year's Golden Bull Award featured nine categories, including "Most Investment Value Award" and "New Quality Enterprise Golden Bull Award," with 55 companies receiving the latter [5] - Sunshine Nuohuo is a professional CRO providing comprehensive drug development services for domestic pharmaceutical companies and research institutions [5] Group 3: Company Performance - For the first three quarters of 2025, Sunshine Nuohuo reported revenue of 856 million yuan and a net profit attributable to shareholders of 163 million yuan [5] - The net cash flow from operating activities reached 148 million yuan, reflecting a year-on-year increase of 36.63% [5]

10月31日，阳光诺和涨5.04%，截至发稿，报58.72元/股，成交1.74亿元，换手率2.70%，总市值65.77亿 元。 资料显示，北京阳光诺和药物研究股份有限公司位于北京市昌平区科技园区双营西路79号院7号楼，成 立日期2009年3月9日，上市日期2021年6月21日，公司主营业务涉及仿制药开发、一致性评价及创新药 开发等方面的综合研发服务,服务内容主要包括药学研究、临床试验和生物分析。主营业务收入构成 为：CRO业务99.91%，其他(补充)0.09%。 从阳光诺和十大流通股东角度 数据显示，融通基金旗下1只基金位居阳光诺和十大流通股东。融通健康产业灵活配置混合A/B （000727）三季度减持55万股，持有股数200万股，占流通股的比例为1.79%。根据测算，今日浮盈赚 取约564万元。 融通健康产业灵活配置混合A/B（000727）成立日期2014年12月25日，最新规模18.16亿。今年以来收益 13.2%，同类排名5437/8154；近一年收益8.7%，同类排名6141/8046；成立以来收益173.5%。 融通健康产业灵活配置混合A/B（000727）基金经理为万民远。 截至发稿，万民远累 ...

Core Viewpoint - 阳光诺和 is a leading drug research outsourcing service provider in China, specializing in generic and innovative drug development services, with strong technical capabilities and extensive project experience [1] Group 1: Business Overview - 阳光诺和 was established on March 9, 2009, and listed on the Shanghai Stock Exchange on June 21, 2021, with its registered and office address in Beijing [1] - The main business includes generic drug development, consistency evaluation, and innovative drug development, covering pharmaceutical research, clinical trials, and bioanalysis [1] Group 2: Financial Performance - For Q3 2025, 阳光诺和 reported revenue of 856 million yuan, ranking 11th among 29 companies in the industry, while the industry leader, 药明康德, achieved revenue of 32.857 billion yuan [2] - The net profit for the same period was 164 million yuan, placing the company 7th in the industry, with 药明康德 leading at 12.206 billion yuan [2] - The company's CRO business generated 590 million yuan, accounting for 99.91% of total revenue, while other business segments contributed 549,700 yuan [2] Group 3: Financial Ratios - As of Q3 2025, 阳光诺和's debt-to-asset ratio was 47.30%, higher than the previous year's 45.65% and the industry average of 22.79% [3] - The gross profit margin for Q3 2025 was 50.75%, down from 52.15% year-on-year but still above the industry average of 37.70% [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 6.76% to 9,204, while the average number of circulating A-shares held per account decreased by 6.33% to 12,200 [5] - The sixth largest circulating shareholder is 融通健康产业灵活配置混合A/B, holding 2 million shares, down by 550,000 shares from the previous period [5] Group 5: Strategic Developments - 华鑫证券 noted that 阳光诺和 plans to acquire 朗研生命 to enhance its industrial layout, aiming for a "CRO + pharmaceutical industry" strategy [6] - The company’s self-developed innovative drug STC007 injection is entering a critical clinical stage, with expectations for at least one product to enter clinical trials by 2026 [6] - Revenue forecasts for 阳光诺和 from 2025 to 2027 are projected at 1.259 billion, 1.415 billion, and 1.615 billion yuan, respectively, with corresponding EPS of 2.06, 2.41, and 2.96 yuan [6]

Core Viewpoint - 阳光诺和's revenue and net profit have declined in the first three quarters of 2025, primarily due to the impact of policy changes on its generic drug business [1] Financial Performance - The company reported a revenue of 856 million yuan, representing a year-on-year decrease of 6.65% [1] - The net profit attributable to the company was 163 million yuan, down 21.38% year-on-year [1] Business Impact - The decline in revenue is attributed to the effects of centralized procurement and the MAH (Marketing Authorization Holder) system [1] - Increased cost rates and new equity incentive expenses during the reporting period contributed to the decrease in net profit [1]

Core Viewpoint - Sunshine Nuohuo (688621.SH) reported a decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved total operating revenue of 856 million yuan, representing a year-on-year decrease of 6.65% [1] - The net profit attributable to shareholders was 163 million yuan, down 21.38% year-on-year [1] - Basic earnings per share were reported at 1.49 yuan [1]

证券代码：688621 证券简称：阳光诺和 公告编号：2025-091 北京阳光诺和药物研究股份有限公司 关于召开 2025 年三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 会议召开时间：2025 年 11 月 10 日(星期一) 上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 30 日(星期四) 至 11 月 07 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sun-novo.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-090 北京阳光诺和药物研究股份有限公司 第二届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"上市公司"） 于2025年10月29日召开第二届董事会第二十五次会议。本次会议通知于2025年10 月24日以直接送达、传真与邮件方式发出，会议由董事长利虔先生召集和主持， 会议应出席董事9名，实际出席董事9名，会议的召集和召开符合《中华人民共和 国公司法》（以下简称"《公司法》"）及《北京阳光诺和药物研究股份有限公司章 程》（以下简称"《公司章程》"）等法律、行政法规、部门规章、规范性文件的 规定。 二、董事会会议审议情况 经与会董事认真审议，一致通过如下决议： （一）审议通过《关于公司 2025 年三季度报告的议案》 公司2025年三季度报告的编制和审核程序符合法律、法规及《公司章程》、 公司内部管理制度的各项规定。公允地反映了公司2025年第三季度的财务 ...

Company Performance - Sunshine Nuohong reported a revenue of approximately 856 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 6.65% [1] - The net profit attributable to shareholders was approximately 163 million yuan, down 21.38% year-on-year [1] - Basic earnings per share were 1.49 yuan, reflecting a decrease of 19.46% compared to the previous year [1] Market Context - As of the report, Sunshine Nuohong's market capitalization stood at 6.5 billion yuan [2] - The A-share market has recently surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with technology leading the market's new "slow bull" trend [2]